These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 31983593)
1. Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study. Gao R; Gabr A; Mouli S; Riaz A; Kulik L; Lewandowski RJ; Salem R J Vasc Interv Radiol; 2020 Mar; 31(3):401-408.e1. PubMed ID: 31983593 [TBL] [Abstract][Full Text] [Related]
2. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Salem R; Gabr A; Riaz A; Mora R; Ali R; Abecassis M; Hickey R; Kulik L; Ganger D; Flamm S; Atassi R; Atassi B; Sato K; Benson AB; Mulcahy MF; Abouchaleh N; Asadi AA; Desai K; Thornburg B; Vouche M; Habib A; Caicedo J; Miller FH; Yaghmai V; Kallini JR; Mouli S; Lewandowski RJ Hepatology; 2018 Oct; 68(4):1429-1440. PubMed ID: 29194711 [TBL] [Abstract][Full Text] [Related]
3. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres. Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356 [TBL] [Abstract][Full Text] [Related]
4. Multicenter Evaluation of Survival and Toxicities of Hepatocellular Carcinoma following Radioembolization: Analysis of the RESiN Registry. Frantz S; Matsuoka L; Vaheesan K; Petroziello M; Golzarian J; Wang E; Gandhi R; Collins Z; Brower J; Rachakonda VM; Du L; Kennedy AS; Sze DY; Lee J; Brown DB J Vasc Interv Radiol; 2021 Jun; 32(6):845-852. PubMed ID: 33812981 [TBL] [Abstract][Full Text] [Related]
5. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma. Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889 [TBL] [Abstract][Full Text] [Related]
6. Yttrium-90 Glass-Based Microsphere Radioembolization in the Treatment of Hepatocellular Carcinoma Secondary to the Hepatitis B Virus: Safety, Efficacy, and Survival. Biederman DM; Titano JJ; Lee KM; Pierobon ES; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Tabori NE; Nowakowski FS; Kim E J Vasc Interv Radiol; 2015 Nov; 26(11):1630-8. PubMed ID: 26321014 [TBL] [Abstract][Full Text] [Related]
7. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study. Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133 [TBL] [Abstract][Full Text] [Related]
8. Safety of Radioembolization in the Setting of Angiographically Apparent Arterioportal Shunting. Thornton LM; Geller BS; Pepin EW; Shah JL; Kapp M; Toskich BB J Vasc Interv Radiol; 2018 Nov; 29(11):1511-1518. PubMed ID: 30293727 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S; J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371 [TBL] [Abstract][Full Text] [Related]
10. Radioembolization for Intermediate-Stage Hepatocellular Carcinoma Maintains Liver Function and Permits Systemic Therapy at Progression. Ranganathan S; Gabr A; Entezari P; Gordon AC; Riaz A; Desai K; Thornburg B; Kulik L; Kalyan A; Salem R; Lewandowski RJ J Vasc Interv Radiol; 2023 Jun; 34(6):968-975. PubMed ID: 36791957 [TBL] [Abstract][Full Text] [Related]
11. Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma. Gabr A; Abouchaleh N; Ali R; Baker T; Caicedo J; Katariya N; Abecassis M; Riaz A; Lewandowski RJ; Salem R J Vasc Interv Radiol; 2018 Nov; 29(11):1502-1510.e1. PubMed ID: 30268638 [TBL] [Abstract][Full Text] [Related]
12. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745 [TBL] [Abstract][Full Text] [Related]
13. Outcomes in Patients with Macrotrabecular-Massive Subtype Hepatocellular Carcinoma Treated with Yttrium-90 Transarterial Radioembolization. Balli HT; Piskin FC; Sozutok S; Erdoğan KE; Aikimbaev K J Vasc Interv Radiol; 2024 Jul; 35(7):998-1003. PubMed ID: 38548131 [TBL] [Abstract][Full Text] [Related]
14. Abouchaleh N; Gabr A; Ali R; Al Asadi A; Mora RA; Kallini JR; Mouli S; Riaz A; Lewandowski RJ; Salem R J Nucl Med; 2018 Jul; 59(7):1042-1048. PubMed ID: 29217739 [TBL] [Abstract][Full Text] [Related]
15. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227 [TBL] [Abstract][Full Text] [Related]
16. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study. Abdallah MA; Wongjarupong N; Hassan MA; Taha W; Abdalla A; Bampoh S; Onyirioha K; Nelson M; Glubranson LA; Wiseman GA; Fleming CJ; Andrews JC; Mahipal A; Roberts LR Expert Rev Gastroenterol Hepatol; 2020 Jul; 14(7):619-629. PubMed ID: 32490691 [TBL] [Abstract][Full Text] [Related]
17. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Sangro B; Carpanese L; Cianni R; Golfieri R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Van Buskirk M; Bilbao JI; Ettorre GM; Salvatori R; Giampalma E; Geatti O; Wilhelm K; Hoffmann RT; Izzo F; Iñarrairaegui M; Maini CL; Urigo C; Cappelli A; Vit A; Ahmadzadehfar H; Jakobs TF; Lastoria S; Hepatology; 2011 Sep; 54(3):868-78. PubMed ID: 21618574 [TBL] [Abstract][Full Text] [Related]
18. The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization. Sukato DC; Tohme S; Chalhoub D; Han K; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A J Vasc Interv Radiol; 2015 Jun; 26(6):816-24.e1. PubMed ID: 25824315 [TBL] [Abstract][Full Text] [Related]
19. Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres. Kwok PC; Leung KC; Cheung MT; Lam TW; Szeto LT; Chou SQ; Chia NH; Tong CM; Yuen PK; Cheung CH; Law CK J Gastroenterol Hepatol; 2014 Nov; 29(11):1897-904. PubMed ID: 24734957 [TBL] [Abstract][Full Text] [Related]
20. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA Trials; 2012 Aug; 13():144. PubMed ID: 22913492 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]